BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 225
- Registration Number
- NCT04531540
Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT04531527
A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 28
- Registration Number
- NCT04524910
- Locations
- π¨π¦
Many Locations, Multiple Locations, Canada
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 704
- Registration Number
- NCT04523220
- Locations
- πΊπΈ
East L.A. Dialysis Center, Los Angeles, California, United States
π΅π±Wojewodzki Szpital Zespolony, Kielce, Poland
π¬π·HIPPOKRATION General Hospital of Athens, Athens, Greece
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 46
- Registration Number
- NCT04521361
- Locations
- π¦πΉ
Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
π«π·Institut du Cancer de Montpellier - Val d'Aurelle, Montpellier Cedex, France
π«π·Centre Hospitalier Lyon Sud, Pierre Benite, France
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 480
- Registration Number
- NCT04519619
- Locations
- π―π΅
Many locations, Multiple Locations, Japan
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1180
- Registration Number
- NCT04516161
- Locations
- πΊπΈ
Bayer Flatiron Xofigo Registry database, Whippany, New Jersey, United States
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT04511611
- Locations
- π―π΅
Medical Co. LTA Nishikumamoto hospital, Kumamoto, Japan
π―π΅Fukuoka Mirai Hospital, Fukuoka, Japan
π―π΅Sumida Hospital, Sumida-ku, Tokyo, Japan
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT04511637
- Locations
- π―π΅
Fukuoka Mirai Hospital, Fukuoka, Japan
π―π΅Medical Co. LTA Nishikumamoto hospital, Kumamoto, Japan
π―π΅Sumida Hospital, Sumida-ku, Tokyo, Japan
Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 48
- Registration Number
- NCT04510987
- Locations
- π©πͺ
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Β© Copyright 2024. All Rights Reserved by MedPath